Vaccine Market 2017 - Forecast to 2022 - Focus on Therapeutic Vaccines

News provided by

Aug 30, 2017, 11:00 ET

DUBLIN, August 30, 2017 /PRNewswire/ --

The "Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022" report has been added to Research and Markets' offering.

The vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 34.30 Billion in 2017, at a CAGR of 7.5%. Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the vaccine market.

This report segments the vaccines market into technology, type, disease indication, route of administration, end user, and region. Based on technology, the vaccine market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate vaccines segment is expected to account for the largest share of the global market, in 2017.

Based on the end user, the vaccines market is segmented into pediatrics and adults. The adult segment is expected to register the highest CAGR during the forecast period. Factors like the increasing investments by companies for the development of new adult vaccines and government initiatives for immunization are driving the growth of this segment.

In 2017, North America is expected to dominate the market, followed by Europe. The high growth of the North American market is attributed to the factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines.

While North America is expected to dominate the market in 2017, Asia is expected to register the highest CAGR during the forecast period. The high growth in this market is attributed to increasing investments by companies in the emerging countries of the Asian region such as India and China and rising disposable income.

While the vaccines market presents significant growth opportunities, market growth may be hindered due to the high cost of vaccine development and product recalls. The vaccine market is highly competitive with several big and small players.

Market Dynamics

Drivers

High Prevalence of Infectious Diseases
Rising Focus on Immunization Programs
Growing Government Support for Vaccine Development
Increasing Company Investments Into Vaccine R&D

Restraints

High Cost of Vaccine Development
Product Recalls

Opportunities

High Growth Prospects in Emerging Markets
Focus on Therapeutic Vaccines
Use of Adjuvants in Vaccines

Challenges

Inadequate Access to Vaccines

Burning Issues

Vaccine Pricing

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Vaccine Market, By Technology

8 Vaccine Market, By Type

9 Vaccine Market, By Disease Indication

10 Vaccine Market, By Route of Administration

11 Vaccine Market, By End User

12 Vaccine Market, By Region

13 Competitive Landscape

Abbott Laboratories
Astellas Pharma Inc.
Bavarian Nordic
CSL Limited
Daiichi Sankyo Company Limited
Emergent Biosolutions Inc.
Glaxosmithkline PLC
Green Cross Corporation
Incepta Vaccine Ltd.
Indian Immunologicals Limited
Johnson & Johnson
Medimmune LLC
Merck & Co. Inc.
Mitsubishi Tanabe Pharma Corporation
Panacea Biotec
Paxvax Inc.
Pfizer Inc.
Protein Science Corporation
Pt Bio Farma (Persero)
Sanofi Pasteur SA
Serum Institute of India
Sinovac Biotech Ltd.
Valneva Se
Vbi Vaccines Inc.
Zydus Cadila

For more information about this report visit https://www.researchandmarkets.com/research/v2rp44/vaccine_market_by

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets